We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Antimalarial Compound Improves Forensics of Bloodstains

By LabMedica International staff writers
Posted on 12 Jun 2017
Forensic investigators often use a luminol chemiluminescence test to detect latent bloodstains at crime scenes. More...
Now, researchers have found that combining luminol with the antimalarial drug artemisinin, a natural peroxide, reduces the risk of false positives compared to the traditional method that mainly uses hydrogen peroxide or sodium perborate as coreactants. They also obtained test results using a smartphone, which could provide highly accurate on-scene analyses.

Luminol is often combined with hydrogen peroxide to react with the heme groups in blood, producing the blue chemiluminescent glow. This allows crime scene technicians to detect blood on surfaces. While this test has proven beneficial in numerous criminal investigations, false positives due to interferences from biomolecules and metal ions, as well as from the breakdown products of hydrogen peroxide, can occur.

In an effort to minimize erroneous identifications, Prof. Guobao Xu of ChangChun Institute of Applied Chemistry, Chinese Academy of Sciences (Changchun, Jilin, China) and colleagues investigated the use of artemisinin with luminol as artemisinin is more structurally sound and more resistant to interferences than hydrogen peroxide.

The researchers showed that the luminol-artemisinin combination is more selective than luminol-hydrogen peroxide, resulting in fewer false positives when challenged with components of bleaches and disinfectants, which criminals often use to cover up a misdeed. The method could distinguish blood from coffee, tea, and brown sugar stains.

The study, by Gao W et al, was published May 11, 2017, in the journal Analytical Chemistry.

Related Links:
ChangChun Institute of Applied Chemistry, Chinese Academy of Sciences


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.